C278F mutation of Crouzon craniosynostosis syndrome on receptor trafficking, ubiquitination, degradation, and signaling. We find that FGFR2 C278F exhibits diminished glycosylation, increased degradation, and limited cellular sublocalization in the osteoblastic cell line, MC3T3E1(C4). Additionally, we show that trafficking and autoactivation of wild type FGFR2 is glycosylation-dependent. Both FGFR2 C278F and unglycosylated wild type FGFR2 signal through phospholipase C␥ in a ligand-independent manner as well as exhibit dramatically increased binding to the adaptor protein, Frs2. These findings suggest that autoactive FGFR2 can signal from intracellular compartments. Based upon our results, we propose that the functional signaling of craniosynostosis mutant, autoactive receptors is limited in some cell types by protective cellular responses, such as increased trafficking to lysosomes and proteasomes for degradation.
Fibroblast growth factor receptors (FGFRs) 2 comprise a family of evolutionarily conserved transmembrane proteins known to be critical for the normal development of multiple organ systems/tissue types, including the craniofacial skeleton. FGFRs are receptor tyrosine kinases and elicit signaling via ligand binding, receptor dimerization, autophosphorylation, and subsequent recruitment and activation of docking and adaptor proteins at the plasma membrane. Upon ligand binding, FGFR1 and FGFR2 directly activate PLC␥1 and indirectly activate MAPK (1) . MAPK activation is achieved through recruitment and activation of the docking protein Frs2, followed by binding and activation of adaptor proteins Grb2, Shp2,andSos1 (2) .Frs2-mediatedsignalingalsostimulatesphosphatidylinositol 3-kinase activity through the adaptor proteins Grb2 and Gab1 (3) . Additionally, FGFR1 and FGFR2 are downregulated upon ligand binding by the Frs2-mediated recruitment of the E3 ubiquitin ligase, Cbl (4, 5) .
Mutations in fibroblast growth factor receptors have been linked to a series of human malformation disorders known as the craniosynostosis syndromes. These clinical syndromes typically involve the premature fusion of specific cranial sutures with a resultant characteristic skull shape, midface deficiency, hypertelorism, and proptosis. Clinical diagnosis of a given syndrome is also often based upon the existence (or lack thereof) of associated limb abnormalities, such as syndactyly. It is possible to imagine FGF/FGFR signaling controlling cranial suture development and fusion via several distinct mechanisms. FGF/ FGFR signaling could control preosteoblast/osteoblast recruitment, differentiation, proliferation, or apoptosis. Unfortunately, studies that have attempted to link expression of craniosynostosis mutant FGFRs with these types of changes in cellular phenotype have revealed conflicting and inconsistent results (6 -13) . It is a commonly held belief that the craniosynostosis-associated FGFR mutations act as gain of function mutations in terms of FGF/FGFR signaling. More specifically, Apert syndrome-associated mutations in FGFR2 have been shown to result in alternative ligand binding and increased ligand binding affinity (14, 15) , whereas Crouzon syndromelinked mutations in FGFR2 have been shown to result in ligandindependent autophosphorylation, dimerization, and tyrosine kinase activity (16 -19) .
Whereas it is tempting to assume from these findings that the craniosynostosis-linked FGFR2 mutations result in increased FGF/FGFR signaling, it is worthy to note that studies on the endocytosis, degradation, and recycling of a homologous tyrosine kinase receptor, epidermal growth factor receptor (EGFR), have shown that enhanced ligand binding actually results in diminished receptor-induced signaling (20, 21) . EGFR can be activated by a large number of ligands, each with varying degrees of receptor affinity and receptor-induced signaling. Attempts to elucidate the mechanism by which these ligands induce differential responses through the same receptor have led to the conclusion that higher affinity ligands actually result in lower levels of EGFR-induced signaling. Stimulation of cells with EGF, a high affinity EGFR ligand, has been shown to elicit increased levels of receptor ubiquitination and degradation, with diminished recycling to the plasma membrane, when compared with stimulation with the lower affinity ligands E4T or transforming growth factor-␣ (22, 23) . Strikingly, attempts to elicit MAPK signaling in cells transfected with Apert-associated FGFR2 S252W or Crouzon-associated FGFR2 C342Y showed significantly diminished phosphorylation of MAPK upon ligand stimulation in these cells (13) . Taken together, these results suggest the possibility that the craniosynostosis-linked mutations in FGFRs may not result in increased FGF/FGFR signaling in the conventional sense.
FGFRs are N-glycosylated and can be expressed as unglycosylated, partially glycosylated, or fully glycosylated receptor forms (24) . Protein glycosylation sites are commonly found at sites of change in the secondary structure of a protein and have been suggested to stabilize the overall structure of a protein (25) . Glycosylation is also well known for its role in protein folding and quality control in the ER via the ER-resident lectins, calnexin and calreticulin (26) . More recent data suggest a role for glycosylation in controlling protein subcellular localization and trafficking. It has been suggested that N-glycosylation of EGFR and other cytokine receptors regulates cell surface expression via protection from excessive endocytosis (27) . Additionally, glycosylation of the human nerve growth receptor, TrkA, as well as of the serotonin type 3 receptor has been shown to be critical for plasma membrane targeting and expression (28, 29) . Biotinylation of cell surface expression of FGFR1 in the non-FGFR-expressing cell line, BaF3, shows predominant expression of the fully glycosylated form on the cell surface (30) . This suggests the possibility that glycosylation of FGFRs is critical for cell surface trafficking of this receptor. It has been noted that Crouzon mutant FGFR2 is both reduced in its ability to bind ligand and is preferentially expressed as the lower molecular weight, partially glycosylated form of the receptor, suggesting that this mutant form of the receptor does not reach the cell surface (31) .
In order to better elucidate the biochemical consequences of craniosynostosis syndrome-linked FGFR2 mutations, we have confirmed that a Crouzon syndrome-associated C278F mutation of FGFR2 results in diminished glycosylation, increased receptor autophosphorylation, and dimerization. Receptor expression studies reveal the mutation to increase receptor degradation and to direct receptor trafficking from the ER/Golgi to the proteasome, as opposed to the cell surface in the osteoblastic cell line, MC3T3E1(C4). Further, we show that trafficking of wild type FGFR2 is dependent upon glycosylation and that unglycosylated wild type FGFR2 exists as an autoactive form in terms of ligand-independent dimerization. Finally, we show that both FGFR2 C278F and unglycosylated wild type FGFR2 exhibit dramatically increased binding to PLC␥ and Frs2, suggesting that these autoactive forms of the receptor are able to elicit signaling from internal compartments.
EXPERIMENTAL PROCEDURES

Materials-3-(4,5-Dimethyl-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), U73122, lactacystin, and heparin were all purchased from Sigma. FGF9 was purchased from R&D Systems. Endo-B-N-acetylglucosaminidase H (endo H), MG132, calpstatin, bafilomycin A1, and tunicamycin were all purchased from Calbiochem. Superfect transfection reagent was purchased from Qiagen. Dulbecco's modified Eagle's medium, customformulated ␣-minimal essential medium without ascorbate, and G418 were purchased from Invitrogen. Fetal bovine serum was purchased from Atlanta Biologicals (Lawrenceville, GA). Sulfosuccinimidobiotin and agarose-streptavidin beads were purchased from Pierce, and protein A-Sepharose was purchased from Amersham Biosciences. Endoglycosidase H was purchased from Calbiochem.
Antibodies-Mouse anti-V5 was obtained from Invitrogen (catalog number 46-0705). Rabbit anti-V5 was obtained from Bethyl (A190-120A). Anti-PLC␥ was obtained from Santa Cruz (catalog number sc-81). Anti-ubiquitin was obtained from Chemicon (catalog number AB1690). Anti-phosphotyrosine was obtained from Upstate Biologicals (catalog number 4G10). Horseradish peroxide-conjugated secondary donkey antimouse and donkey anti-rabbit were obtained from Jackson Laboratories. Anti-GM130 and anti-calreticulin were obtained from BD Transduction Laboratories (catalog numbers 610822 and 612136). Fluorescence-conjugated secondary antibodies, Alexa Fluor-488 and Alexa Fluor-568 were obtained from Molecular Probes, Inc. (Eugene, OR).
Plasmid Constructs-Full-length FGFR2IIIc and FGFR2IIIc lacking juxtamembrane valine and threonine residues (at positions 428 and 429) cDNA (GenBank TM number NM_000141) were subcloned into the V5 tag containing mammalian expression vector, pcDNA3.1 (Invitrogen) to create plasmids for wild type FGFR2 and adaptor protein Frs2 binding-deficient FGFR2 (FGFR2/ϪVT). The Crouzon syndrome-associated C278F mutation was introduced by in vitro mutagenesis using primer 5Ј-CGGAGGAGACGTAGAGTTTGTCTTCAAGGTTTAC-AGTGATGCC-3Ј. Similar methods were utilized to create two putative N-glycosylation mutants (primer 5Ј-GGAGAATGA-ATACGGATCCATCCAGCACACGTACCACCTGG-3Ј for FGFR2 N241Q ; primer 5Ј-GGACTGCCGGCACAGGCCTCCA-CAGTGG-3Ј for FGFR2 N265Q ). Mutation of tyrosines 656 and 657 was performed with primer 5Ј-CGCCAGAGATATCAACAATATTGACGAA-GAGAAAAAGACCACCAATGG-3Ј to create tyrosine kinase activity-dead receptor constructs (FGFR2/KD and FGFR2 C278F/KD ). Mutation of tyrosine 769 was performed with primer 5Ј-CACAACCAATGAGGAAGCCTTGGACCTCAG-CCAAC-3Ј to create PLC␥ binding-deficient constructs (FGFR2/PLC␥D and FGFR2 C278F/PLC␥D ). Plasmid pDG268 (ubiquitin-His-green fluorescent protein) was obtained from Doug Gray (University of Ottawa, Canada).
Cell Culture-COS7 cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. MC3T3E1(C4) murine osteoprogenitor cells were cultured in custom formulated, nonascorbate ␣-minimal essential medium containing 10% fetal bovine serum. MC3T3E1(C4) cells were cultured in nonascorbate media to prevent osteoblast differentiation (32, 33) . All cells were cultured at 37°C in a humidified atmosphere of 5% CO 2 .
Establishment of FGFR2-expressing Cells-Stable cell lines were established by transfection of 85% confluent COS7 cells in 10-cm 2 plates with 5 g of plasmid and Superfect reagent, following the manufacturer's protocol. Transfectants were selected by growth in media containing 500 g/ml G418. Unless otherwise indicated, transient transfections were performed utilizing similar methods.
Immunoprecipitation and Immunoblots-Preparation of cell lysate was achieved by solubilization in RIPA buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1% nadeoxycholate, 1% Triton X-100, 0.1% SDS) containing 1ϫ protease inhibitor mixture (Sigma), followed by removal of insoluble material by centrifugation at 12,000 rpm for 10 min. Prior to loading, 5ϫ Laemmli loading buffer was added to a final 1ϫ concentration, samples were boiled for 3 min and then iced. For immunoprecipitations, all experiments were done on ice or at 4°C. Cells were lysed in 1 ml of RIPA containing 1ϫ protease inhibitor mixture (Sigma) and precleared with 50 l of protein A-Sepharose rotating for 1 h. The indicated antibody was added to precleared lysate, and samples were rotated for an additional 1 h. 50 g of protein A-Sepharose was added to each tube, and samples were left rotating overnight. Immune complexes were washed four times with RIPA buffer. Immunoprecipitated proteins were released from beads by boiling for 3 min in 25 l of 2ϫ Laemmli buffer. Samples were separated by SDS-PAGE and transferred onto Immobilon (Millipore Corp.). Immunoreactive protein bands were visualized by ECL (Amersham Biosciences).
Biotinylation-Transfected cells were washed in phosphatebuffered saline, pH 8.0, five times on ice. Cells were incubated with sulfosuccinimidobiotin on ice for 30 min. Cells were washed five times in 100 mM glycine/phosphate-buffered saline, pH 8.0, and lysed in 1 ml of RIPA buffer containing 1ϫ protease inhibitor mixture. After the removal of insoluble protein by centrifugation, agarose-streptavidin was added, and biotin-streptavidin complexes were allowed to form for 1 h, followed by four washes in RIPA buffer and precipitation.
Immunofluorescence-MC3T3E1(C4) cells were plated on poly-D-lysine (Sigma)-coated coverslips and cultured overnight in ␣-minimal essential media containing 10% fetal bovine serum. 36 h post-transfection, cells were fixed in 4% paraformaldehyde and permeabilized in phosphate-buffered saline, 0.25% Triton. The cells were then blocked in phosphate-buffered saline plus 10% bovine serum albumin and incubated in phosphate-buffered saline plus 3% bovine serum albumin and the indicated primary antibodies, followed by incubation with fluorescent conjugated secondary antibodies. Nuclei were counterstained with 4Ј,6-diamidino-2-phenylindole. Cells were visualized and photographed on a Zeiss Axioscop2 fluorescent microscope.
MTT Assays-COS7 stable transfectants were plated in 96-well plates and cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. After the indicated growth periods and treatments, medium was replaced with 1 g/ml MTT in phosphate-buffered saline, pH 7.4, followed by incubation at 37°C for 3 h. MTT solution was removed, and cells were incubated overnight in lysis buffer at 37°C. Reduction of MTT was measured by spectrophotometric readings at A 570 .
Microphysiometry-COS7 stable transfectants were plated at 100,000 cells/well in 60-mm 2 transwell plates (Costar) and grown for 5 days in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Monolayer cultures were transferred to a Cytosensor microphysiometer (Molecular Devices) for measurements of cellular acid production. Basal level cellular acid production was measured with cells bathed in 1 mM phosphate-buffered saline. Cellular acid production was also measured upon challenging cells with 5 mM sodium azide (blocks aerobic respiration) and 5 mM oxamate (blocks anaerobic respiration).
RESULTS
Crouzon Syndrome-associated Mutation Diminishes Glycosylation and Increases Degradation of FGFR2-The C278F mutation of FGFR2 is commonly associated with craniosynostosis of Crouzon syndrome. Because craniosynostosis is thought to reflect effects of FGFR2 C278F on osteoblast function, we employed the murine osteoblastic cell line, MC3T3E1(C4). Initial attempts to express FGFR2 C278F in MC3T3E1(C4) cells led to extremely low levels of protein expression. Multiple subclones of stably transfected cells showed significant mRNA levels but minimal protein expression of the receptor (data not shown). In order to determine if this was the result of diminished biosynthesis versus increased degradation of FGFR2 C278F , MC3T3E1(C4) cells were transiently transfected with equivalent amounts of V5-tagged wild type and C278F mutant FGFR2 constructs and cultured in the presence of protease inhibitors. V5 tag immunoblots revealed apparent differences in both glycosylation and degradation of the wild type and C278F mutant receptors (Fig. 1) . Wild type FGFR2 was expressed predominantly as the fully glycosylated, 120-kDa form of the receptor, whereas FGFR2 C278F was expressed predominantly as a partially glycosylated, 110-kDa form of the receptor. Proteasome inhibition by treatment with either MG132 or lactacystin increased protein expression of FGFR2 C278F to levels similar to those of wild type receptor. Of note, both proteasome inhibitors stabilized predominantly the 110-kDa form of FGFR2 C278F . Inhibition of lysosome acidification by bafilomycin appears to predominantly stabilize the 120-kDa form of FGFR2 C278F . Crouzon Syndrome-associated Mutation Diminishes Glycosylation and Increases Receptor Autophosphorylation-We chose to study the C278F mutation of FGFR2, because it is the most common mutation associated with Crouzon syndrome (itself the most common of the craniosynostosis syndromes). The C278F mutation is analogous to a C342R mutation of FGFR2 that has been previously shown to result in diminished receptor glycosylation and increased receptor autoactivation (31) . In order to confirm that the 110-kDa form of FGFR2 C278F is the result of diminished receptor glycosylation, cell lysate of cells transiently transfected with FGFR2 C278F was digested with the enzyme, endoglycosidase H, that is specific for the high mannose N-linked oligosaccharides characteristic of proteins that have not completed Golgi-mediated maturation of glycosylation. V5 tag immunoblots confirmed that both the 120-and 110-kDa receptor forms result from N-glycosylation ( Fig. 2A) . Endoglycosidase digestion of cell lysate from cells transfected with FGFR2
C278F shows a shift in molecular mass from a primarily 110-kDa band to a primarily 85-kDa band. This 85-kDa band represents the unglycosylated receptor form, as confirmed by tunicamycin treatment of whole cell lysate from cells transfected with FGFR2.
FGFR2 is a receptor tyrosine kinase that exhibits increased tyrosine phosphorylation upon receptor activation. In order to confirm that the C278F mutation of FGFR2 increases receptor autoactivation, we tested for basal levels of tyrosine phosphorylation of FGFR2 C278F , as compared with wild type FGFR2. Phosphotyrosine immunoblotting of V5 tag immunoprecipitates from cells transfected with FGFR2 or FGFR2 C278F clearly indicated that FGFR2 C278F exhibits increased basal levels of tyrosine phosphorylation (Fig. 2B) . C278F as compared with wild type receptor (Fig. 3A) . Wild type FGFR2 was expressed throughout the cell and revealed a clear cellular outline, suggestive of cell surface localization. FGFR2 C278F , on the other hand, was expressed in a limited, perinuclear pattern that is suggestive of localization in the ER and/or Golgi compartments. Cells expressing FGFR2
C278F did not show a clear cellular outline, suggesting that this receptor variant was not expressed on the cell surface. To examine this possibility biochemically, cell surface proteins of transiently transfected MC3T3E1(C4) cells were covalently modified with a cell-impermeant biotin derivative. Biotinylated proteins were precipitated with streptavidin-coated beads and analyzed by SDS-PAGE, revealing that wild type FGFR2 was present at the cell surface, whereas FGFR2 C278F was not (Fig.  3B ). Probing the immunoblot for the cytoplasmic protein, pyruvate kinase, confirmed that the whole cell lysate but not the streptavidin precipitate contained cytoplasmic proteins. Probing the blot for streptavidin confirmed that equivalent amounts of biotinylated membrane proteins were loaded on the gel for wild type and C278F mutant FGFR2. 
FIGURE 2. Crouzon syndrome-associated C278F mutation diminishes receptor glycosylation and increases receptor autophosphorylation.
A, Crouzon syndrome-associated FGFR2 C278F exhibits incomplete glycosylation. COS7 cells were transiently transfected with FGFR2 or FGFR2 C278F and treated with 10 g/ml tunicamycin to inhibit N-glycosylation for 24 h where indicated. 10 g of cell lysate was digested with endoglycosidase H at 37°C for 9 h, as indicated, prior to immunoblotting with anti-V5 antibody. Endoglycosidase H digestion of cell lysate from FGFR2 C278F -transfected cells converted the majority of the 110-kDa receptor form to a form with a molecular mass of 85 kDa, similar to the size of wild type FGFR2 in which N-glycosylation was blocked by culture with tunicamycin, indicating that the majority of FGFR2 C278F exists as an immature glycosylation form. B, Crouzon syndromeassociated FGFR2 C278F exhibits receptor autoactivity. COS7 cells were transiently transfected with FGFR2 or FGFR2 C278F and immunoprecipitated with anti-V5 antibody. Immunoblotting (IB) for phosphotyrosine reveals increased basal level tyrosine phosphorylation for FGFR2 C278F as compared with wild type receptor.
receptor showed that, whereas a portion of this receptor form did co-localize with the ER marker, calreticulin, there was extensive expression outside of this compartment ( C278F is somewhat more stable. Of note, whereas FGFR2 C278F was predominantly expressed as the 110-kDa, partially glycosylated form of FGFR2 in COS7 cells, biotinylation experiments suggest that some of this glycosylation form does reach the cell surface in this cell line (data not shown).
The association of incomplete glycosylation with altered trafficking of FGFR2 C278F led us to question the role that glycosylation plays in the trafficking of the wild type receptor. In order to test the idea that glycosylation is critical for cell surface trafficking of FGFR2, we used an inhibitor of N-glycosylation, tunicamycin, to compare cell surface expression of normally glycosylated FGFR2 and FGFR2 lacking N-glycosylation in COS7 cells. Treated cells expressed only the 85-kDa form of the receptor. Biotinylation of cell surface proteins indicated that this 85-kDa form does not reach the cell surface (Fig. 5A) . These results suggest that N-glycosylation of FGFR2 is critical for normal trafficking of the receptor.
FGFR2 has multiple potential N-glycosylation sites. We wished to know whether N-glycosylation of any particular site was required for normal trafficking of the receptor. Further, we wished to eliminate the possibility that altered trafficking of FGFR2 in the presence of tumicamycin resulted indirectly from a nonspecific effect on ER function. For these reasons, we mutated several potential glycosylation sites in FGFR2. SDS-PAGE analysis of cell lysates from MC3T3E1(C4) cells transiently transfected with two such mutants revealed that the N265Q mutation diminished glycosylation in this cell type, whereas the N241Q mutation had little effect (Fig. 5B) revealed a ubiquitous staining pattern with a clear cellular outline reminiscent of wild type FGFR2 (Fig. 5C ). Finally, in order to biochemically confirm the finding that glycosylation is necessary for normal trafficking of FGFR2, biotinylation for cell surface proteins was performed on COS7 cells transfected with FGFR2 N265Q . Immunoblot analysis revealed greatly diminished cell surface expression of the glycosylation-defective receptor variant as compared with wild type receptor (Fig. 5D) . Similar results were obtained in the MC3T3 cell line (Fig. 11C) . C278F is not expressed on the cell surface in MC3T3E1(C4) cells. Cells were transiently transfected with FGFR2 constructs, and cell surface proteins were biotinylated and precipitated with streptavidin beads. Streptavidin precipitates (avi ppt) and whole cell lysate aliquots were analyzed by SDS-PAGE. Immunoblot analysis (IB) with antibody against V5 epitope tag shows wild type FGFR2 but not FGFR2 C278F evident in cell surface fractions. Specificity of cell surface protein labeling by biotinylation was confirmed by reprobing the immunoblots for the cytoplasmic protein, pyruvate kinase. Blots were reprobed with horseradish peroxidase-conjugated strepavidin to confirm that equivalent amounts of protein were loaded on the gel for wild type and C278F mutant FGFR2.
FGFR2
C278F and Unglycosylated FGFR2 Exhibit Increased Ubiquitination-Degradation of FGFRs at the plasma membrane is known to be mediated by phosphorylation of the docking protein, Frs2, followed by recruitment of the Cbl ubiquitin ligase via the adaptor protein, Grb2 (4). Ubiquitination resulted in down-regulation of the receptor, via proteasomal and/or lysosomal degradation. Our observation that FGFR2 C278F exhibited an ER/Golgi-restricted expression pattern and was degraded via proteasomes and lysosomes in MC3T3E1(C4) cells, whereas interfering with glycosylation of FGFR2 in COS cells reduced cell surface expression, suggested that these effects might be mediated by ubiquitination. In support of this hypothesis, we found that tunicamycin treatment of COS7 cells transfected with wild type or C278F mutant receptor caused enhanced ubiquitination of the unglycosylated, 85-kDa form of FGFR2 (Fig. 6) . Significantly, FGFR2 C278F appeared to be ubiquitinated in the absence of tunicamycin treatment, whereas wild type FGFR2 did not. Of note, the 85-kDa form of FGFR2 C278F appears to be preferentially ubiquitinated.
FGFR2 C278F and Incompletely Glycosylated FGFR2 Exhibit Increased Dimerization-The C278F mutation in FGFR2 eliminates a cysteine residue in the extracellular IgIII domain of the receptor and is analogous to a C342R mutation that has previously been shown to result in increased disulfide-linked dimerization of the receptor (19) . Due to the striking similarities in trafficking and ubiquitination patterns of the incompletely glycosylated wild type receptor and the C278F mutant receptor, we hypothesized that incompletely glycosylated FGFR2 would exhibit ligand-independent dimerization and activation similar to that of FGFR2
C278F
. To investigate this possibility, FGFR2 or FGFR2 C278F expressed by transient transfection in COS7 was immunoprecipitated and characterized by electrophoresis under nonreducing conditions. This experiment confirms that the C278F mutation results in formation of disulfide-linked receptor dimers (Fig. 7) . Tunicamycin treatment of these cells promoted formation of disulfide-linked dimers of wild type FGFR2 as well as FGFR2 C278F .
FGFR2
C278F and Unglycosylated FGFR2 Bind and Activate PLC␥-Although conventional cell signaling models involve initiation of signaling cascades of receptor tyrosine kinases by ligand binding at the cell surface, more recent findings suggest that some of these same cell signaling pathways can be initiated at internal compartments (35) . The findings that both partially glycosylated and unglycosylated FGFR2 forms exhibit increased receptor dimerization yet minimal cell surface expression led us to ask if these forms of the receptor could initiate signaling. PLC␥ is one of the major signal transducers downstream of FGFRs and has recently been shown to be capable of initiating signaling from within the Golgi compartment (36) . In order to determine if pharmacological inhibition of FGFR2 N-glycosylation or the C278F mutation of FGFR2 with associated diminished glycosylation promotes signaling through PLC␥, co-immunoprecipitation experiments were performed on transiently transfected COS7 cells. PLC␥ immunoblots of immunoprecipitates of V5-tagged FGFR2 showed that inhibition of N-glycosylation resulted in dramatically increased receptor binding to PLC␥. Significantly, FGFR2
C278F exhibited increased PLC␥ binding in the absence of tunicamycin treatment. This binding was completely eliminated by mutation of the tyrosine at position 860 that is necessary for recruitment and activation of PLC␥ (Fig.  8A) . The preferential association of PLC␥ with immature glycosylation forms of FGFR2 was confirmed by immunoprecipitation of PLC␥ followed by immunoblot analysis of the receptor. This experiment showed that PLC␥ preferentially binds the 110-and 85-kDa glycosylation forms of FGFR2 and exhibits minimal binding to the mature, 120-kDa form of the receptor under these conditions (i.e. without ligand stimulation). As expected, mutation of the tyrosine at position 860 of FGFR2 eliminated FGFR2 from PLC␥ immunoprecipitates (Fig. 8B) .
Immunoblot analysis of PLC␥ in anti-phosphotyrosine immu- N241Q has a molecular mass (120 kDa) similar to that of wild type FGFR2, whereas FGFR2 N265Q has a reduced molecular mass (110 kDa), indicating that FGFR2 N241Q is normally N-glycosylated, whereas FGFR2 N265Q is not. C, immunofluorescent imaging suggests that glycosylation-defective FGFR2 is not expressed on the cell surface. MC3T3E1(C4) cells were transiently transfected and immunostained for V5-FGFR2 protein. a, V5-tagged FGFR2 N241Q or FGFR2 N265Q immunostained with fluorescein isothiocyanate, with 4Ј,6-diamidino-2-phenylindole nuclear co-stain. b, as in a with extended photographic exposure. c, as in b with handtraced cellular outline. D, chemically labeling cell surface proteins confirms that glycosylation-defective FGFR2 is not expressed on the cell surface. COS7 cells were transiently transfected, and cell surface proteins were isolated by biotinylation and streptavadin bead precipitation. Streptavidin bead precipitates and whole cell lysate aliquots were analyzed by SDS-PAGE. Immunoblot analysis with antibody against V5 epitope tags reveals an absence of FGFR2 N265Q on the cell surface as compared with wild type receptor. FIGURE 6. FGFR2 C278F and unglycosylated wild type FGFR2 exhibit increased ubiquitination. COS7 cells were co-transfected with receptor and ubiquitin constructs and treated with 10 g/ml tunicamycin for 24 h to inhibit receptor N-glycosylation, as indicated. Ubiquitinated receptor was detected by immunoprecipitation with anti-ubiquitin antibody followed by SDS-PAGE analysis and immunoblotting with anti-V5 antibody. WCL, whole cell lysates.
FIGURE 7. FGFR2
C278F and unglycosylated wild type FGFR2 exhibit increased receptor dimerization. COS7 cells were transiently transfected and treated with 10 g/ml tunicamycin for 24 h to inhibit receptor N-glycosylation, as indicated. Extended chemiluminescent exposure of V5 tag immunoprecipitates, immunoblotted for exogenous receptor, shows dimers present in all lanes except untreated, wild type FGFR2.
noprecipitates showed that PLC␥ is tyrosine-phosphorylated in cells expressing wild type FGFR2 when N-glycosylation was inhibited, in the absence of ligand. This analysis also showed dramatically increased tyrosine phosphorylation of PLC␥ in cells expressing FGFR2 C278F in the absence of ligand compared with cells expressing wild type FGFR2 (Fig. 8C) .
FGFR2 C278F and Incompletely Glycosylated FGFR2 Bind Frs2-Frs2 is an adaptor protein that allows FGFRs to signal through phosphatidylinositol 3-kinase and MAPK upon ligand binding at the cell surface. Whereas it has been suggested that the myristylation of Frs2 limits its expression to the plasma membrane, it is worthy to note that another protein exhibiting membrane tethering via covalently attached lipid, Ras, has been shown to be activated on internal membranes (36) . The finding that partially glycosylated and unglycosylated FGFR2 binds and activates PLC␥ led us to hypothesize that these receptor forms also signal through Frs2. To test this hypothesis, co-immunoprecipitation experiments were performed on COS7 cells that had been transiently transfected with plasmids encoding FGFR2 and Myc epitope-tagged Frs2. Immunoprecipitation of FGFR2 followed by immunoblot analysis to detect Frs2/Myc showed that inhibition of N-glycosylation causes dramatically increased association of Frs2 with FGFR2. Strikingly, FGFR2 C278F exhibited increased Frs2 binding, relative to wild type FGFR2, in the absence of tunicamycin treatment. The increase in Frs2 binding to FGFR2 C278F or to FGFR2 following inhibition of glycosylation was lost upon elimination of the juxtamembrane, valine/threonine, Frs2 binding site (Fig. 9) .
Glycosylation-deficient FGFR2
N265Q
Exhibits Increased Receptor Autoactivity and Binding to PLC␥-In order to eliminate the possibility that increased signaling of unglycosylated 
prior to immunoprecipitation (IP) and immunoblot analysis (IB).
A, FGFR2
C278F and unglycosylated FGFR2 exhibit increased binding to PLC␥. FGFR2 proteins were immunoprecipitated with anti-V5 and were resolved by SDS-PAGE, and immunoblots were processed with anti-PLC␥. B, PLC␥ exhibits preferential binding to 110-and 85-kDa forms of FGFR2. Anti-PLC␥ immunoprecipitates were analyzed by SDS-PAGE and probed for FGFR2 protein. C, PLC␥ is phosphorylated in cells expressing FGFR2 C278F or unglycosylated FGFR2 in a ligand-independent manner. Transfected cells were serumstarved and then treated with FGF9 and heparin for 15 min prior to lysis. Anti-phosphotyrosine immunoprecipitates were analyzed by SDS-PAGE, and immunoblots were probed for PLC␥. WCL, whole cell lysates. FGFR2 results from a nonspecific effect of tunicamycin treatment, we tested for autoactivity of the glycosylation-deficient receptor, FGFR2 N265Q . To investigate receptor dimerization, FGFR2 or FGFR2 N265Q expressed by transient transfection in COS7 were immunoprecipitated and characterized by electrophoresis under nonreducing conditions. This experiment confirmed that the N265Q mutation resulted in increased formation of receptor dimers (Fig. 10A) . In order to confirm that the glycosylation deficiency is itself a cause of receptor autoactivation, we then tested for basal levels of tyrosine phosphorylation of FGFR2
N265Q
, as compared with wild type FGFR2. Phosphotyrosine immunoblotting of V5 tag immunoprecipitates from cells transfected with FGFR2 or FGFR2 N265Q clearly indicated that FGFR2 N265Q exhibited increased basal levels of tyrosine phosphorylation (Fig. 10B) .
In order to determine if the glycosylation deficiency induced by the N265Q mutation promotes signaling through PLC␥, co-immunoprecipitation experiments were performed on transiently transfected COS7 cells. Significantly, PLC␥ immunoblots of FGFR2 immunoprecipitates revealed increased binding to the PLC␥ by FGFR2 N265Q receptor as compared with wild type FGFR2 in the absence of tunicamycin (Fig. 10C) .
Co-immunoprecipitation experiments employing COS7 cells that had been transiently transfected with plasmids encoding FGFR2 or FGFR2 N265Q and Myc epitopetagged Frs2 were performed in order to determine if FGFR2 N265Q also exhibits increased binding to Frs2. Detection of V5-FGFR2 on anti-V5 immunoblots of Frs2 immunoprecipitates revealed that the diminished N-glycosylation caused by the N265Q mutation does not result in dramatically increased binding to Frs2 (Fig. 10D) .
Intracellular Retention of Poorly Glycosylated FGFR2 Is Independent of Receptor Signaling-Pharmacological inhibition of N-glycosylation of FGFR2 in COS7 cells, which inhibits trafficking of FGFR2 to the cell surface, promotes ligand-independent activation of the receptor. Is the autoactivation of FGFR2 associated with diminished glycosylation responsible for the altered receptor trafficking? To address this question, we examined the trafficking behavior of kinase-inactive (FGFR2/KD) and PLC␥ binding-deficient (FGFR2/PLC␥D) forms of the receptor. COS7 cells were transiently transfected with constructs encoding FGFR2, FGFR2/KD, or FGFR2/PLC␥D, and receptor N-glycosylation was inhibited by tunicamycin. Receptor trafficking to the cell surface was assessed by biotinylation and streptavidin/bead precipitation of cell surface proteins followed by detection of FGFR2 on immunoblots. Both the kinase-inactive and PLC␥ binding-deficient receptor mutants remained intracellular and did not traffic to the cell surface when N-glycosylation was inhibited (Fig. 11, A and B) .
Tunicamycin treatment is well known to induce ER stress and is likely to have many effects upon a cell. To more thoroughly examine the role that receptor activation plays in the trafficking of glycosylation-deficient FGFR2, we next investigated the effect of tyrosine kinase activity on trafficking of ). Receptor trafficking to the cell surface was assessed by biotinylation and streptavidin/bead precipitation of cell surface proteins followed by V5 tag detection of FGFR2 on immunoblots. Strikingly, both FGFR2 C278F and FGFR2 C278F/KD exhibited diminished cell surface expression, as compared with wild type FGFR2 (Fig. 11C) . Therefore, we conclude that incomplete glycosylation itself, rather than the premature activation of FGFR2 associated with incomplete glycosylation, is responsible for the failure of this receptor to traffic normally to the cell surface.
Expression of FGFR2
C278F Results in Increased Levels of Cellular MTT Reduction-Soon after establishing COS7 cell lines stably transfected with wild type and C278F mutant FGFR2, we noted that cells expressing FGFR2 C278F tended to acidify their media to a much greater extent than their wild type counterparts. After 5-7 days of culture, cells expressing FGFR2 C278F acidified their media as assessed by changes in phenol red pH indicator dye, whereas the cells expressing wild type receptor did not, and this difference did not appear to reflect significant differences in cell density between the two stable cell populations. After establishing that cell lines expressing wild type FGFR2 and FGFR2 C278F expressed equivalent amounts of transfected receptor (Fig. 12A) , assays of MTT reduction were performed in an attempt to establish the cause of the increased acid production by FGFR2 C278F -expressing cells. Reduction of MTT, a tetrazolium salt, is commonly used as an indicator of increased levels of cellular metabolism and/or cell number. Results of MTT assays show that cells expressing FGFR2 C278F exhibit significantly increased levels of MTT reduction as compared with untransfected cells or cells transfected with wild type receptor. This phenotypic difference appears to be cell density-dependent, since significant differences are found only when a greater number of cells are plated (Fig. 12B) . FIGURE 11 . Intracellular retention of incompletely glycosylated FGFR2 is independent of receptor signaling activity. A, intracellular retention of incompletely glycosylated FGFR2 is independent of receptor kinase activity. COS7 cells were transiently transfected with kinase-inactive FGFR2 (FGFR2/ KD), treated with 10 g/ml tunicamycin for 24 h as indicated, and cell surface proteins were biotinylated. Streptavidin precipitates (avi ppt) and whole cell lysate aliquots were analyzed by SDS-PAGE. Immunoblots (IB) with anti-V5 antibody show that FGFR2/KD from control cultures is expressed on the cell surface, whereas FGFR2/KD from tunicamycin-treated cultures is not. B, intracellular retention of unglycosylated FGFR2 is independent of receptor PLC␥ signaling. COS7 cells were transiently transfected with V5-tagged mutant FGFR2 deficient in PLC␥ binding (FGFR2/PLC␥D) and subjected to analysis as described for Fig. 9A . C, intracellular retention of FGFR2 C278F is independent of receptor tyrosine kinase activity. MC3T3E1(C4) cells were transiently transfected with V5-tagged constructs encoding FGFR2 C278F , a kinase-inactive FGFR2 C278F (FGFR2 C278F/KD ) or the glycosylation-deficient FGFR2 N265Q , and cell surface proteins were biotinylated. Streptavidin precipitates (avi ppt) and whole cell lysate aliquots were analyzed by SDS-PAGE. Immunoblots with anti-V5 antibody show that wild type FGFR2 is expressed on the cell surface, but FGFR2 C278 , FGFR2 C278F/KD and FGFR2 N265Q are not. Specificity of cell surface protein labeling by biotinylation was confirmed by reprobing the immunoblots for the cytoplasmic protein, pyruvate kinase. Blots were reprobed with horseradish peroxidase-conjugated strepavidin to confirm that equivalent amounts of protein were loaded on the gel for each FGFR2 construct. 
C278F Increases Basal Levels of Anaerobic Glycolysis-Although cellular reduction of MTT is commonly attributed to mitochondrial metabolic pathways, cytoplasmic pathways also contribute to an extent that may predominate in some cell types (37, 38) . To more definitively identify the metabolic pathways influenced by FGFR2 C278F , the COS7 stable transfectants were subjected to microphysiometry, which quantifies cellular acid production. Microphysiometry data confirm that FGFR2 C278F -expressing cells exhibit increased levels of cellular metabolism. This increase appears to be primarily due to an increase in lactate dehydrogenase-dependent anaerobic respiration. Challenging cells with an inhibitor of aerobic respiration increases cellular acid production to similar levels in control cells or cells transfected with FGFR2 or FGFR2
C278F
, most likely as a result of compensatory increased anaerobic respiration under these conditions. Challenging cells with an inhibitor of anaerobic glycolysis specifically diminishes cellular acid production of FGFR2 C278F receptor-expressing cells to levels equivalent to wild type receptor-expressing cells and untransfected cells (Fig. 13) . Thus, the results of assays of MTT reduction and the results of microphysiometry are both consistent with the interpretation that FGFR2 C278F promotes anaerobic metabolism.
Increased Cellular Reduction of MTT Is Dependent upon PLC␥ and Frs2 Signaling-Does the enhanced anaerobic metabolism caused by FGFR2
C278F result from the ER/Golgi retention of FGFR2 C278F or the ligand-independent activation that is associated with ER/Golgi retention? To address this question, we generated stably transfected COS7 cells expressing FGFR2
C278F variants with specific signaling deficiencies. Mutation of tyrosines 656 and 657 eliminates tyrosine kinase activity of the receptor (1) (data not shown). Mutation of tyrosine 769 abolishes binding and activation of PLC␥ (39) . Elimination of the juxtamembrane valine and threonine residues at positions 428 and 429 specifically eliminates the FGFR binding site for Frs2 (40) . This Frs2 binding-deficient receptor variant has been shown to activate PLC␥ but not MAPK signaling upon ligand binding (39) . Immunoblot analysis showed that stable COS cell lines expressed similar amounts of each of the receptor variants. Of note, each of these FGFR2 C278F variants is predominantly expressed as the partially glycosylated, 100-kDa receptor form (Fig. 14A) . Mutation of the kinase activity C278F increases basal levels of anaerobic glycolysis. A, transfected COS7 cells stably expressing V5-tagged FGFR2 constructs were subjected to immunoblot analysis. Anti-V5 immunoblots of 15 g of cell lysate show that COS7 cell lines express equivalent amounts of wild type FGFR2 and FGFR2 C278F . B, transfected COS7 cells stably expressing V5-tagged FGFR2 constructs were plated and grown for 5 days prior to assay. Cellular acid production was monitored by microphysiometry under basal level conditions (phosphate-buffered saline; PBS) and upon challenges with inhibitors of aerobic glycolysis (azide) and anaerobic glycolysis (oxamate; Ox). *, p Ͻ 0.01, not statistically different versus wild type FGFR2-expressing cells. ) also abolished the differences in levels of MTT reduction between wild type-and mutant-expressing cells (Fig. 14B) , suggesting that signaling via both PLC␥ and phosphatidylinositol 3-kinase or MAPK pathways is required to promote anaerobic metabolism.
DISCUSSION
Differences in expression levels of FGFR2 C278F and wild type FGFR2 in an osteoblastic cell line are largely eliminated in the presence of inhibitors of proteasomal or lysosomal function, indicating that FGFR2 C278F is poorly expressed, because it is degraded more rapidly than wild type FGFR2. Immunoblot analysis of FGFR2 C278F confirms previous reports that Crouzon-linked mutations in FGFR2 result in predominant expression of a lower molecular weight, incompletely glycosylated form of the receptor (32) .
Treatment with proteasome and lysosome inhibitors also lends insight into possible mechanisms of FGFR2 trafficking and degradation. Inhibition of lysosome acidification leads to increased protein levels of the mature 120-kDa form of both wild type and mutant receptor, with minimal changes in the 110-kDa form of the receptor. This suggests that it is only the mature, fully glycosylated form of the receptor that is degraded in lysosomes. Conversely, proteasome inhibition appears to stabilize predominantly the 110-kDa form of FGFR2 C278F . This result would suggest that proteasomes preferentially mediate degradation of the partially glycosylated receptor. The preferential expression of the 120-kDa form on the cell surface and the 110-kDa form in ER/Golgi membranes suggests that cell surface FGFR2 is degraded mainly by trafficking to lysosomes, whereas ER/Golgi-resident FGFR2 is degraded by proteasomes. Degradation of FGFRs has previously been shown to be mediated by ubiquitination, in an Frs2-dependent manner. However, expression of FGFRs in Frs2 Ϫ/Ϫ cells resulted in only partial rescue from degradation, suggesting that the receptors are degraded by more than one mechanism (4), in agreement with our findings.
The finding that Crouzon mutant FGFR2 C278F is expressed predominantly in a partially glycosylated form, combined with the finding that the mechanism of receptor degradation appears to be glycosylation-dependent, led us to question whether FGFR2
C278F was being trafficked to the cell surface to the same extent as wild type FGFR2. Through immunofluorescent staining and biotinylation of cell surface proteins, we show that the Crouzon C278F mutation alters receptor subcellular localization and significantly diminishes cell surface expression in MC3T3E1(C4) cells. These results are in contrast to those of Galvin et al. (18) , who showed similar cell surface immunofluorescent staining for both wild type and Crouzon mutant (Y340H, C342Y, S354C) FGFR or FGFR/Neu chimeric receptors in NIH3T3 cells, although these authors also concluded that there was increased expression of mutant receptors on internal membranes (18) . One likely explanation for this apparent discrepancy is that trafficking and localization of mutant FGFR2 is cell type-specific. Our results demonstrate that the 110-kDa partially glycosylated form of FGFR2 does not traffic to the cell surface in MC3T3E1(C4) cells, whereas it does so to some extent in COS7 cells.
Immunofluorescent co-staining for ER and Golgi markers in MC3T3E1(C4) cells confirms that Crouzon C278F mutant receptor is expressed predominantly within these intracellular compartments, whereas wild type receptor is found both within and outside of these compartments. This is consistent with our conclusion that the C278F mutation results in receptor retention in the ER and Golgi followed by trafficking to lysosomes or proteasomes for degradation. It is important to note that, although FGFR2
C278F is not expressed significantly on the cell surface in MC3T3E1(C4) cells, this does not necessarily mean that it is never trafficked to the plasma membrane. The greatly diminished proportion of FGFR2 C278F present at the cell surface might result either from less efficient trafficking to the cell surface or from more rapid endocytosis and degradation after trafficking to the cell surface. Our results suggest that both mechanisms may contribute, since FGFR2 C278F stability is enhanced by both proteasome and lysosome inhibitors. We have shown that blocking acidification of lysosomes increases the level of expression of a fully glycosylated from of the mutant receptor. Our data suggest that a fraction of FGFR2 C278F is fully glycosylated and trafficked to the cell surface but then is immediately subject to endocytosis and trafficking to lysosomes for degradation. Previous findings that Crouzon mutant FGFRs do not bind FGFs are consistent with our conclusion that the mutant receptors are not found to any significant extent on the cell membrane (16) .
Our findings suggest that FGFR2 is trafficked in a glycosylation-dependent manner, such that unglycosylated and partially glycosylated receptor are trafficked from the ER/Golgi to the proteasome for degradation, whereas fully glycosylated receptor is trafficked to the cell surface for signaling. The mechanism by which glycosylation controls receptor trafficking is unclear. Carbohydrate moieties may act as tags to directly indicate where a protein should be trafficked (42) . Glycosylation and oligosaccharide processing have long been known to play a major role in protein folding and quality control in the ER (43) . It has been noted that misfolded proteins are deglycosyolated and ubiquitinated prior to proteasome-mediated degradation during the ER quality control response (42) .
Our findings also suggest that glycosylation prevents premature FGFR2 dimerization. Tunicamycin treatment of cells expressing wild type receptor or mutation of a critical glycosylation residue both lead to dramatically increased levels of disulfide-linked FGFR2 dimers. Additionally, we have shown that incompletely glycosylated FGFR2 is not expressed to a significant extent on the cell surface. It seems likely then that incompletely glycosylated FGFRs dimerize in the ER/Golgi and are then trafficked to proteasomes for degradation. Dimerization of receptor tyrosine kinases leads to autophosphorylation with subsequent recruitment and activation of other proteins. However, our studies indicate that the premature activation of receptors that accompanies retention in the ER and/or Golgi is not responsible for that retention. It appears that a lack of glycosylation and/or premature receptor dimerization is itself adequate to prevent FGFR2 from being expressed on the cell surface. It is important to note here that the mechanisms that control the trafficking of unglycosylated FGFR2 and partially glycosylated FGFR2 C278F may differ. Although conventional cell signaling models would suggest that receptor tyrosine kinases cannot signal from internal compartments due to lack of access to adaptor proteins and second messengers, more recent data suggest that cell signaling can be initiated from internal compartments. The phosphoinositide, phosphatidylinositol 3,4,5-trisphosphate, generated upon endocytosis of activated receptor tyrosine kinases has been shown to occur at both the plasma membrane and at internal ER/Golgi membranes. Phosphatidylinositol 3,4,5-trisphosphate generation is an indicator of receptor tyrosine kinase signaling through phosphatidylinositol 3-kinase. Treatment of cells with platelet-derived growth factor resulted in delayed but stronger phosphatidylinositol 3,4,5-trisphosphate generation on ER/Golgi membranes than that seen at the plasma membrane (35) . Additionally, PLC␥ has been shown to activate Ras on the Golgi membrane (36) . PLC␥ is one of the major downstream targets of FGFRs (1) . We have shown that FGFR2 C278F and incompletely glycosylated FGFR2 dimerize without ligand, exhibit increased basal levels of tyrosine phosphorylation, and exhibit limited cell surface expression patterns. Here we also show that these autoactive forms of FGFR2 are able to bind and activate PLC␥. Additionally, we show that PLC␥ preferentially binds to the incompletely glycosylated, 110-kDa, and 85-kDa forms of FGFR2 under these conditions. FGFR2
C278F and unglycosylated FGFR2 also exhibit dramatically increased binding to Frs2. Of note, partially glycosylation-deficient FGFR2 N265Q did not appear to exhibit increased binding to Frs2. This result suggests that incomplete glycosylation is itself inadequate to initiate signaling through this adaptor protein. Taken together, our results indicate that FGFR2 C278F signals from internal compartments.
Ubiquitination has been shown to play a critical role in the endocytosis and degradation of multiple tyrosine kinase receptors (44), including FGFRs (4). Ubiquitination is also thought to be a tag for misfolded proteins that are trafficked from the ER to the proteasome for degradation in the ER quality control response (42) . Trafficking of wild type FGFR2 with N-glycosylation inhibition and trafficking of FGFR2 C278F from the ER and Golgi compartments to proteasomes for degradation should result in increased ubiquitination. Our data confirm this prediction. Ubiquitination appears preferential for the incompletely glycosylated forms of the receptor, with minimal ubiquitination evident on the 120-kDa receptor form of FGFR2. These findings are consistent with the idea that autoactive forms for FGFR2 that fail to complete glycosylation are trafficked directly from the ER/Golgi to proteasomes for degradation.
Both assays of MTT reduction and microphysiometric measurements indicate that FGFR2 C278F expression in COS7 cells influences cellular metabolism, whereas wild type FGFR expression does not. Microphysiometry data suggest that this increase is due to an increase in anaerobic respiration. This result is consistent with previous reports that the majority of MTT reduction in some cell types is due to cytosolic NADHdependent mechanisms (37, 38) . It is interesting to note that this is clearly a cell density-dependent phenomenon, since significant differences arise only when a greater number of cells are plated. One possible explanation for this cell density-dependent increase in anaerobic respiration is that it is primarily a response to conditions of high cell stress. Under conditions of cell confluence in a monolayer culture, cells may be under stressful conditions due to limited nutrients and exposure to high levels of toxic metabolites. In this scenario, cell culture under these conditions uncovers a cell phenotype such that only cells expressing the C278F mutant receptor respond to the metabolic stress by increasing levels of anaerobic glycolysis. This finding is highly reminiscent of the Warburg effect. The Warburg effect, originally described by Otto Warburg in 1930, describes the phenomenon of increased glycolysis in cancer cells. This effect has more recently been proposed as fundamental to the process of cellular transformation (45) . Our finding that the expression of FGFR2 C278F dramatically increases levels of anaerobic glycolysis suggests the possibility that expression of this mutant receptor may contribute to cellular transformation.
In order to confirm that changes in cell metabolism are the result of signaling from the mutant receptor, COS7 cells were transfected with FGFR2 C278F receptor variants that are deficient in specific signaling capacities. As expected, mutation of the kinase activity domain of FGFR2 abolished the increased levels of MTT reduction found in cells expressing FGFR2 C278F . Curiously, stable expression of FGFR2 C278F variants lacking either the ability to bind PLC␥ or the ability to bind Frs2 also abolished the increase of MTT reduction in cells expressing these FGFR2
C278F variants, suggesting that this cellular phenotype requires both PLC␥-and Frs2-mediated signaling from FGFR2 C278F . Our findings raise an important question in regard to craniosynostosis-linked FGFR2 mutations and cancer. FGFR2 is widely expressed in normal human adult tissues. More specifically, the mesenchymal FGFR2 isoform, FGFR2IIIc, is highly expressed in smooth muscle tissue of the stomach and gastrointestinal tract, as well as in cardiac myocytes and the myometrium of the uterus (46) . It is well known that excessive tyrosine kinase signaling (such as that due to chromosomal translocation-induced FGFR1 fusion proteins) plays a causal role in myeloproliferative disorder and lymphoblastic lymphoma (47) . Additionally, high expression levels of FGFR2 are found in gastric cancers and are correlated with poor prognosis (48) . We have shown that stable expression of FGFR2 C278F in COS7 cells results in a dramatic up-regulation of glycolysis, a phenomenon that is suggestive of cellular transformation. Taken together, these findings would suggest that patients carrying the craniosynostosis-linked FGFR2 mutations should exhibit a higher incidence of cancer. The fact that this is not the case suggests that these mutations do not elicit constitutive FGF/FGFR signaling in the conventional sense. The lack of increased cancer incidence in these patients also suggests that signaling from craniosynostosis mutant receptors in otherwise normal cells is somehow limited in the ability to alter cellular phenotype. It is noteworthy that the metabolic alterations induced by FGFR2 C278F were observed in COS7 cells, a highly artificial cell type in which FGFR2 C278F is not subject to the efficient degradation observed in the more physiologically relevant MC3T3E1(C4) cell line. Our data suggest that, in some cell types, retaining autoactive forms of FGFR2 in the ER/Golgi leading to increased ubiquitination and trafficking directly to the proteasome for degradation may represent a protective checkpoint against cellular transformation.
Finally, our results raise new questions concerning the mechanism by which FGFR2 mutations influence craniosynostosis. Our findings indicate that, depending on the cell type, autoactivating mutations of FGFR2 might influence cell differentiation by causing enhanced FGFR2 signaling, by causing FGFR2 signaling from an inappropriate subcellular compartment (ER and Golgi versus cell surface and endosomal membranes), or by enhancing FGFR2 degradation to such an extent that total FGFR2 signaling is diminished. In considering this potentially contentious latter possibility, it is important to recall that osteoblast-specific FGFR2IIIc knock-out and FGFR2IIIc knockdown mouse models exhibit a phenotype that includes craniosynostosis (34, 41) . Determination of which of these mechanisms pertains to craniosynostosis may require development of methods to address the extent and subcellular locus of FGFR2 activation in situ.
